Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
News

Annual Guide to Jewish Genetic Diseases

Below are diseases that are often screened for in Jewish couples who are planning to have children because of an elevated risk of carrying a recessive mutation. Researchers so far have identified many more genetic diseases affecting those of Ashkenazi heritage than those of Sephardic descent.

Ashkenazi Disorders

Bloom’s Syndrome

Bloom’s syndrome is a recessive disorder characterized by growth deficiency, sun sensitivity, immunodeficiency, and a predisposition to diabetes and cancer. Genes in people with Bloom’s syndrome are more likely to mutate, causing chromosomes to break. The carrier rate is estimated at 1 in 110, according to the Center for Jewish Genetics, resulting in the disease manifesting itself in about 1 in 48,000 births.

Canavan Disease

Canavan disease, which is carried by 1 in 40 to 1 in 58 Ashkenazi Jews, affects the brain and central nervous system. Canavan patients have a deficiency of the enzyme aspartocyclase, which is necessary for normal brain development, and therefore they cannot generate myelin, which insulates nerve cells and allows transmission of nerve impulses.

Familial Hyperinsulinism

Familial or Congenital hyperinsulinism is an autosomal recessive genetic defect occurring in the Ashkenazi Jewish population, among others. About 1 in 66 Ashkenazi Jews is a carrier; 1 in 18,000 has the disease. The disease affects the body’s sulfonylurea receptors in the pancreas, which control the secretion of insulin to regulate the levels of glucose in the bloodstream.

In individuals with the disease, the sulfonylurea receptor system is impaired, so the beta cells of the pancreas keep secreting insulin, regardless of the blood sugar level. This causes dangerously low blood-sugar levels, which can result in seizures, brain damage and death.

Cystic Fibrosis

Cystic fibrosis (CF) is a progressive multi-system disorder caused by abnormal function of the CFTR protein, which causes the body to produce thick, sticky mucus in the lungs and digestive system. CF is no more common among Ashkenazi Jews than among other Caucasians, and is in fact one of the most common genetic disorders among Jews and non-Jews alike. One in 28 is a carrier; 1 in 3,000 has CF.

Factor XI Deficiency

Factor XI is a coagulation enzyme which binds to platelets to stop bleeding. Deficiency of Factor XI causes a (usually) mild bleeding disorder that can become more serious after surgery, tooth extraction or injury. About 1 in 8 are carriers and 1 in 190 are affected.

Factor XI deficiency was originally called hemophilia C, and is also known as plasma thromboplastin antecedent (PTA) deficiency. Hemophilia A is Factor VIII deficiency and hemophilia B is Factor IX deficiency.

Familial Dysautonomia

Familial dysautonomia (FD, also known as Riley Day syndrome) is a progressive neurogenetic disorder that affects the sensory and autonomic nervous systems. It is estimated that about 1 in 31 AshkenaziJews is a carrier of the FD gene and 1 in 3,700 has the disease.

Intelligence is usually normal in affected individuals; however, learning disabilities are common.

Fanconi Anemia

Fanconi anemia is a fatal, recessive disorder that causes bone marrow failure and possible birth defects. One in 90 people of Ashkenazi Jewish ancestry carries a Fanconi anemia gene. One in 32,000 has the disease. Many do not reach adulthood.

Gaucher Disease

Gaucher Disease (pronounced “go-shay”) is an inherited disorder caused by a defective gene which prevents the body from producing sufficient amounts of an important enzyme, glucocerebrosidase. That enzyme plays a critical role in the complex process the body uses to remove and recycle worn-out cells. The disease course is quite variable, ranging from no outward symptoms to severe disability and death. Gaucher Disease affects all ethnicities, but Jewish people of Ashkenazi descent are affected in greater numbers. Approximately 1 in 16 are carriers and 1 in 855 have Gaucher disease. Among the general population, approximately 1 in 100/200 are carriers, while about 1 in 60,000 have the disease.

Glycogen Storage Disease, Type I

Glycogen is a carbohydrate that serves as one of the primary fuel reserves for the body’s energy needs. Stores of glycogen power the body during times of fasting and exercise. Glycogen storage disease type I (GSD I) is caused by an enzyme deficiency that prevents the body from completely breaking down the stored glycogen into glucose, which the body metabolizes. This progressive buildup of glycogen can cause impaired growth, bleeding problems and enlarged liver and kidneys. In Ashkenazi Jews, the carrier rate is 1 in 71 and 1 in 20,000 have the disease.

Joubert Syndrome

There are several types of Joubert syndrome, caused by mutations in different genes. Joubert syndrome 2, is most common in Ashkenazi Jews, and is caused by a mutation in the TMEM216 gene. It is a rare neurological disorder characterized by multiple brain abnormalities, including the absence or underdevelopment of the cerebellar vermis — an area of the brain that controls balance and coordination. The carrier rate is 1 in 92; and 1 in 34,000 have the disease.

Maple Syrup Urine Disease

Maple syrup urine disease (MSUD) is named for the characteristic sweet smell of the urine in affected children. It is caused by genetic mutations that prevent the body from breaking down three specific amino acids in the body. These products then build up to toxic levels, leading to the manifestations of the disease. MSUD is caused by mutations in four different genes. There are several forms of this disease, and the classic severe form is most common in Ashkenazi Jews. Carrier frequency is 1 in 81 while 1 in 50,000 have the disease.

Mucolipidosis IV

ML4, first described in 1974, is characterized by the deficiency of a transport protein that plays a crucial role in psychomotor development. One out of 100 Ashkenazi Jews is a carrier, but the disease rate is unclear because many cases may be confused with cerebral palsy or present with only mild symptoms.

Nemaline Myopathy

There are several types of nemaline myopathy, caused by mutations in different genes. It primarily affects skeletal muscles, It causes muscle weakness (myopathy) throughout the body, but it is typically most severe in the muscles of the face, neck, and limbs. This weakness can worsen over time. The muscle problems associated with nemaline myopathy are caused by an abnormal buildup of thread-like structures (nemaline bodies) in certain muscle tissue. The carrier rate is 1 in 108; about 1 in 47,000 has the disease.

Niemann-Pick

Niemann-Pick disease includes several subtypes, two of which (types A and B) stem from a deficiency of acid sphingomyelinase, an enzyme that breaks down a fatty substance called sphingomyelin. As a result of the enzyme deficiency, the unprocessed fat accumulates, mainly in the spleen, lymph nodes and brain. About 1 in 100 Ashkenazi Jews is a carrier of Niemann-Pick Type A, which is neuro-degenerative and leads to death by 2 or 3 years of age. One in 40,000 have the disease. Type B is a milder disorder that does not affect the brain but results in complication of the liver, spleen, lungs and bone marrow. Additional variants of this enzyme deficiency exist, ranaging between types A and B in degree of severity. These depend on how much active acid sphingomyelinase is present in the cells to process the fats.

Nonclassical Adrenal Hyperplasia

NCAH results from a defect in an enzyme necessary for the conversion of cholesterol to cortisol, which is the body’s primary stress hormone. Mutations in this gene are also responsible for the much more severe salt-wasting and simple virilizing types of adrenal hyperplasia which present shortly after birth. The non-classical type presents at any time after birth and exhibits much milder symptoms. The carrier rate is relatively high: 1 in 3 people. The disease strikes 1 in 27.

Nonsyndromic Hearing Loss and Deafness

Nonsyndromic hearing loss refers to non-progressive mild-to-profound sensorineural hearing impairment (which means the impairment stems from problems within the ear’s nerves) that is not associated with any other medical problems or physical abnormalities. There are many known causes of nonsyndromic hearing loss, many of which are genetic. One in 20 to 1 in 25 are carriers and 1 in 1,700 has this hearing loss. DFNB1 accounts for half of all congenital, autosomal recessive nonsyndromic hearing loss. DFNB1 is most often caused by mutations in the GJB2 gene, which encodes the connexin 26 protein, and less frequently by mutations in the GJB6 gene, which encodes the connexin 30 protein. One specific mutation in the GJB2 gene is found most commonly in Ashkenazi Jews.

Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) causes degeneration of motor neurons, the nerve cells in an area of the spinal cord known as the anterior horn. When the motor neurons break down, so does the link between the brain and the voluntary muscles — those which we control. As the link between the brain, spinal cord and muscles breaks down, the muscles that are used for activities such as crawling, walking, sitting up and moving the head are used less and less and become weaker, or shrink (atrophy). About 1 in 41 Ashkenazi Jews are carriers, slightly more than the general population. It has recently been added to the standard Ashkenazi screening test, raising the number of diseases to 19.

Tay-Sachs

Tay-Sachs disease is caused by the congenital absence of a vital enzyme, Hexosaminidase-A. Without the enzyme, the body cannot break down one of its fatty substances, which builds up abnormally in the brain and progressively impairs the central nervous system. The gene that causes the infantile form of the disease is present in about 1 in 30 Ashkenazi Jews in America. About 1 in 300 Sephardic Jews and people of non-Jewish descent are also carriers.

Torsion Dystonia

Torsion dystonia (DYT1) is a progressive movement disorder characterized by sustained, twisting muscle spasms. With time, the frequency and duration of these spasms increases, leading to joint contractures and progressive disability. Spasms may be slow or rapid shock-like jerks, which are repetitive and may be rhythmic, and which are often made worse by voluntary movement, stress and fatigue.

Individuals with torsion dystonia have normal early development and normal intelligence. The disease is caused by a mutation in the TOR1A gene, but the underlying mechanism of the disorder is not well understood. Researchers believe that it may be caused by altered communication between the neurons in the brain. The carrier frequency is 1 in 1,000 to 1 in 3,000; the disease affects 1 in 3,000 to 1 in 9,000, according to studies.

Usher Syndrome

Usher syndrome comprises a group of diseases with a distinctive combination of hearing and progressive vision loss. The genes related to Usher syndrome provide instructions for making proteins that play important roles in normal hearing, balance, and vision. They function in the development and maintenance of hair cells, which are sensory cells in the inner ear that help transmit sound and motion signals to the brain. In the retina, these genes are also involved in determining the structure and function of light-sensing cells called rods and cones. Most of the mutations responsible for Usher syndrome lead to a loss of hair cells in the inner ear and a gradual loss of rods and cones in the retina. Degeneration of these sensory cells causes hearing loss, balance problems, and vision loss. The carrier rate is 1 in 107 to 1 in 141, according to the variant. Disease frequency is 1 in 45,000 to 1 in 80,000.

Walker-Warburg Syndrome

Walker-Warburg syndrome (WWS) is a type of congenital muscular dystrophy characterized by brain and eye abnormalities and muscle disease, particularly weakness and atrophy of voluntary muscles. Mutations in different genes lead to different forms of WWS, and the forms vary in regard to muscles involved, ages of onset, and severity. Only the carrier frequency is known: 1 in 149.

Sephardi Disorders

Beta Thalassemia

Red blood cells rely on the protein hemoglobin to transport oxygen from the lungs to the rest of the body. When genetic mutations prevent the production of the beta chain, one of two structures necessary to complete a hemoglobin protein, red blood cells aren’t produced in sufficient quantities, leading to anemia. Globally, Beta thalassemia is the most common inherited single gene disorder. This disorder covers a spectrum of anemias, ranging in severity from mild (intermedia) to severe (thalassemia major or Cooley’s anemia). Individuals with thalassemia intermedia have some residual beta chain production, whereas those with thalassemia major have none. Beta thalassemia is most frequently seen in humid climates with a high incidence of malaria, such as Africa, the Mediterranean, the Middle East and Asia. This is due to the fact that being a carrier is thought to confer some resistance to malaria. For Sephardic Jews, the carrier rate varies by country of origin, for instance, 1 in 30 for Greeks and Italians and 1 in 10 for Iranians.

Familial Mediterranean Fever

Familial Mediterranean fever (FMF) is an episodic condition that affects 1 in 200 Sephardic Jews. About 1 in 3 to 1 in 7 are carriers. A mutation of the MEFV gene is the culprit, hindering the body’s ability to control inflammation when it occurs. A result of the condition is amyloidosis, or potentially dangerous buildup of protein in organs and tissues.

G6PD Deficiency

G6PD deficiency is the most common known human enzyme deficiency, affecting 400 million people worldwide, most frequently in areas with a high incidence of malaria, such as Africa, the Mediterranean and Southeast Asia. About 65 percent of male Kurdish Jews have the disease. Carriers are thought to have some resistance to malaria. Because the genetic mutations are sex-linked, most cases occur in males. Females who carry one mutation are generally not affected because the copy of the gene on the other X chromosome is functioning normally and compensates for the defect. Affected males can pass the mutation to a daughter, but it is unlikely that she would have symptoms, for this reason.

The disease is caused by insufficient glucose-6-phosphate dehydrogenase (G6PD), an enzyme found in red blood cells. Thus, the red blood cells break down faster than they can be replenished. This results in hemolytic anemia, which can vary in severity from lifelong anemia to rare bouts to no symptoms. Anemia can also be induced by certain oxidative drugs, infections, severe stress or ingestion of fava beans. (The most severe form of the disorder is called favism, after the legume.)

Glycogen Storage Disease, Type III

Glycogen storage disease type III (GSD III) is caused by an enzyme deficiency that prevents liver and/or muscle tissue from completely breaking down stored glycogen into glucose, which the body metabolizes. Glycogen is a carbohydrate that serves as one of the primary fuel reserves for the body’s energy needs. Stores of glycogen power the body during times of fasting and exercise. The progressive buildup of glycogen caused by the enzyme deficiency can cause muscle wasting and organ failure. In the Sephardi community, GSD III is primarily found among Jews of North African descent. About 1 in 5,400 North African Jews have this disease and 1 in 35 are carriers.

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning journalism this Passover.

In this age of misinformation, our work is needed like never before. We report on the news that matters most to American Jews, driven by truth, not ideology.

At a time when newsrooms are closing or cutting back, the Forward has removed its paywall. That means for the first time in our 126-year history, Forward journalism is free to everyone, everywhere. With an ongoing war, rising antisemitism, and a flood of disinformation that may affect the upcoming election, we believe that free and open access to Jewish journalism is imperative.

Readers like you make it all possible. Right now, we’re in the middle of our Passover Pledge Drive and we still need 300 people to step up and make a gift to sustain our trustworthy, independent journalism.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Only 300 more gifts needed by April 30

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.